Systemic enzyme treatment
as a method of secondary prevention in patients after myocardial
infarction in the rehabilitation period.
Sledzevskaya I.K., Loboda M.V.,
Kolesnik E.A., Babiy L.N., Fisenko L.I. Systemic enzyme treatment as
a method of secondary prevention in patients after myocardial
infarction in the rehabilitation period. II Mediterranean Congress
of Physical Medicine and Rehabilitation, 20-23 May, 1998, Valencia,
Spain
Abstract: Despite its proved hypolipidemic and immunocorrective
effects, Wobenzym ("Mucos Pharma" Germany) has not been used in
patients with myocardial infarction (MI) in period of
rehabilitations.The aim of this study was the estimation of
influence treatment with Wobenzym on lipids parameters, antioxidant
activity and immunological indices in patients after myocardial
infarction.
30 myocardial infarction patients in 3rd-4th week of the disease
were treated with Wobenzym. The patients also received beta-adrenoblockers,
nitrates, aspirin and inhibitors ACE.
Parallel experimental studies with two rabbit groups with a
hypercholesterolemia model were carried out. Cholesterol content in
plasma, blood pro- and antioxidant parameters and state of blood
monocytes were estimated. Evident hypolipidemic effects (significant
decrease of cholesterol level) and immunocorrecting effects
(significant decrease of titer of antibodies to the infarcted
myocardium and circulating immune complexes) of Wobenzym were
demonstrated in clinical and experimental study.
Based on obtained results it can be recommended to use Wobenzym in
complex treatment of myocardial infarction patients to reduce risk
factors of reinfarction.